These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 1855186)

  • 1. The value of estrogen and progesterone receptor determinations in advanced breast cancer. Estrogen receptor level but not progesterone receptor level correlates with response to tamoxifen.
    Bezwoda WR; Esser JD; Dansey R; Kessel I; Lange M
    Cancer; 1991 Aug; 68(4):867-72. PubMed ID: 1855186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
    Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
    J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study.
    Ravdin PM; Green S; Dorr TM; McGuire WL; Fabian C; Pugh RP; Carter RD; Rivkin SE; Borst JR; Belt RJ
    J Clin Oncol; 1992 Aug; 10(8):1284-91. PubMed ID: 1634918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distribution, frequency, and quantitative analysis of estrogen, progesterone, androgen, and glucocorticoid receptors in human breast cancer.
    Allegra JC; Lippman ME; Thompson EB; Simon R; Barlock A; Green L; Huff KK; Do HM; Aitken SC
    Cancer Res; 1979 May; 39(5):1447-54. PubMed ID: 427788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study.
    Elledge RM; Green S; Pugh R; Allred DC; Clark GM; Hill J; Ravdin P; Martino S; Osborne CK
    Int J Cancer; 2000 Mar; 89(2):111-7. PubMed ID: 10754487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The correlation of estrogen and progesterone receptor levels with response to chemotherapy for advanced carcinoma of the breast.
    Paone JF; Abeloff MD; Ettinger DS; Arnold EA; Baker RR
    Surg Gynecol Obstet; 1981 Jan; 152(1):70-4. PubMed ID: 7455895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer.
    Konecny G; Pauletti G; Pegram M; Untch M; Dandekar S; Aguilar Z; Wilson C; Rong HM; Bauerfeind I; Felber M; Wang HJ; Beryt M; Seshadri R; Hepp H; Slamon DJ
    J Natl Cancer Inst; 2003 Jan; 95(2):142-53. PubMed ID: 12529347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative estrogen and progesterone receptor levels related to progression-free interval in advanced breast cancer patients treated with megestrol acetate or tamoxifen.
    Bonomi P; Gale M; Von Roenn J; Anderson K; Johnson P; Wolter J; Economou S
    Semin Oncol; 1988 Apr; 15(2 Suppl 1):26-33. PubMed ID: 3368797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy.
    Kuukasjärvi T; Kononen J; Helin H; Holli K; Isola J
    J Clin Oncol; 1996 Sep; 14(9):2584-9. PubMed ID: 8823339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative progesterone receptor expression and efficacy of anti-estrogen therapy in breast cancer.
    Luoh SW; Ramsey B; Park B; Keenan E
    Breast J; 2014; 20(1):46-52. PubMed ID: 24261828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Change of influence of prognostic markers on metastasis free interval during and after adjuvant tamoxifen therapy in breast cancer patients.
    Abu Rabi Z; Todorovic-Rakovic N; Markicevic M; Stamatovic L; Vujasinovic T; Nikolic-Vukosavljevic D
    J BUON; 2013; 18(2):321-7. PubMed ID: 23818341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
    Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
    J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progesterone receptor quantification as a strong prognostic determinant in postmenopausal breast cancer women under tamoxifen therapy.
    Lamy PJ; Pujol P; Thezenas S; Kramar A; Rouanet P; Guilleux F; Grenier J
    Breast Cancer Res Treat; 2002 Nov; 76(1):65-71. PubMed ID: 12408377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Tamoxifen-induced progesterone receptors in breast tumors].
    Tsyrlina EV; Semiglazov VF; Nurgaziev KSh; Ivanova OA
    Vopr Onkol; 1991; 37(9-10):916-21. PubMed ID: 1842650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Up-regulation of estrogen receptor by tamoxifen in human breast cancer.
    Noguchi S; Motomura K; Inaji H; Imaoka S; Koyama H
    Cancer; 1993 Feb; 71(4):1266-72. PubMed ID: 8382104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increase of progesterone receptor by tamoxifen as a hormonal challenge test in breast cancer.
    Namer M; Lalanne C; Baulieu EE
    Cancer Res; 1980 May; 40(5):1750-2. PubMed ID: 7371003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary hormonal therapy of advanced breast cancer with megestrol acetate: predictive value of estrogen receptor and progesterone receptor levels.
    Bonomi P; Johnson P; Anderson K; Wolter J; Bunting N; Strauss A; Roseman D; Shorey W; Economou S
    Semin Oncol; 1985 Mar; 12(1 Suppl 1):48-54. PubMed ID: 3975653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. St. Gallen endocrine response classes predict recurrence rates over time.
    Koornstra RH; Beelen KJ; Vincent AD; van der Noort V; van Diest PJ; Linn SC
    Breast; 2015 Dec; 24(6):705-12. PubMed ID: 26429398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-proliferative activity, progesterone receptor status, estrogen receptor level, and clinical outcome of estrogen receptor-positive advanced breast cancer.
    Paradiso A; Tommasi S; Mangia A; Lorusso V; Simone G; De Lena M
    Cancer Res; 1990 May; 50(10):2958-62. PubMed ID: 2334898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive value of tumor estrogen and progesterone receptor levels in postmenopausal women with advanced breast cancer treated with toremifene.
    Valavaara R; Tuominen J; Johansson R
    Cancer; 1990 Dec; 66(11):2264-9. PubMed ID: 2147123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.